Cannabis for Endometriosis

Understanding Endometriosis

Endometriosis is a chronic inflammatory condition in which tissue similar to the uterine lining (endometrium) grows outside the uterus — most commonly on the ovaries, fallopian tubes, pelvic peritoneum, bladder, bowel, and in severe cases the diaphragm or pleural cavity. Like normal endometrial tissue, ectopic lesions respond to hormonal fluctuations, swelling and bleeding with each menstrual cycle — but with no exit route. The result is intense local inflammation, adhesion formation, scarring, and in many cases severe chronic pain.

Symptoms vary considerably but typically include: severe dysmenorrhoea (menstrual cramps disproportionate to bleeding severity), chronic pelvic pain outside of menstruation, deep dyspareunia (pain during intercourse), dyschezia (painful bowel movements, especially during menstruation), dysuria (painful urination), and profound fatigue. A majority of patients also develop secondary anxiety, depression, and sexual health difficulties as consequences of uncontrolled chronic pain.

Despite affecting approximately 10% of women of reproductive age, endometriosis is systematically under-diagnosed. The average diagnostic delay from symptom onset to confirmed diagnosis is 7–10 years globally — driven by normalisation of menstrual pain, limited awareness among general practitioners, and the requirement for laparoscopic biopsy to confirm diagnosis definitively.

Conventional treatment limitations are significant. NSAIDs (ibuprofen, naproxen) provide modest relief for mild-to-moderate dysmenorrhoea but are inadequate for severe endo pain. Combined hormonal contraceptives suppress symptoms but cannot be used long-term by all patients and do not prevent progression. GnRH agonists and antagonists (creating medical menopause) cause bone density loss, menopausal symptoms, and cardiovascular effects with prolonged use. Laparoscopic excision surgery is the most effective intervention but has a 5-year recurrence rate of 30–50% and requires access to skilled surgeons.

The endocannabinoid system and Endometriosis: A Specific Biological Connection

The therapeutic potential of cannabis for endometriosis is not merely based on general pain-relieving properties — there is a specific and remarkable biological connection between the ECS and endometriotic lesions themselves.

CB1 and CB2 Overexpression in Endometriotic Tissue

A seminal 2010 study by Bouchard et al. published in the American Journal of Pathology demonstrated that endometriotic lesions express significantly higher levels of CB1 and CB2 receptors compared to eutopic (normal uterine) endometrium in the same patients. Furthermore, the enzyme FAAH (which degrades anandamide) showed reduced expression in endometriotic tissue, suggesting that the local ECS environment in ectopic lesions may already be altered. CB1 activation in endometriotic cells reduced their survival and invasiveness in vitro — raising the tantalising preclinical possibility that cannabinoids might directly inhibit lesion growth, not merely manage pain.

The PGE2 Prostaglandin Pathway

Prostaglandin E2 (PGE2) is a central mediator of endometriosis-associated pain. Endometriotic lesions produce higher levels of COX-2 (cyclooxygenase-2) than normal endometrium, leading to elevated local PGE2 that drives vasodilation, sensitises pain receptors, and promotes oestrogen synthesis in lesions (creating a self-sustaining oestrogenic environment). CBD inhibits COX-2 expression and reduces PGE2 production — the same mechanism as NSAIDs, but through a different molecular pathway. This means CBD may provide anti-inflammatory pain relief that is potentially additive with NSAIDs rather than redundant.

Anandamide and Nerve Fibre Density

Research by Mechsner et al. (2009) found that the peritoneal fluid of endometriosis patients contains elevated levels of nerve growth factor (NGF), which drives proliferation of pain-sensing nerve fibres into and around endometriotic lesions. Anandamide, the endogenous CB1 ligand, inhibits NGF-stimulated nerve fibre growth in vitro. By elevating anandamide levels (through FAAH inhibition by CBD), cannabis may reduce the hypersensitivity of peripheral sensory fibres innervating endo lesions — directly addressing the peripheral sensitisation component of endo pain.

The QIMR Berghofer Research

The landmark study by Armour, Sinclair, Ng, and Smith — published in the Journal of Obstetrics and Gynaecology Canada in 2019 and drawing on data from the Australian EndoZone patient registry — provided the first peer-reviewed quantitative data on cannabis use specifically in endometriosis patients. Key findings from the 484-participant survey:

• 13% of respondents currently used cannabis to manage endometriosis symptoms.
• Of cannabis users, 96.4% reported it was very or moderately effective for pelvic pain relief — a higher satisfaction rate than reported for any other self-management strategy in the survey, including exercise, diet modification, and heat therapy.
• Cannabis users reported significant reductions in use of prescription pain medications, including opioids, since starting cannabis.
• Most common use: inhaled (smoked or vapourised) cannabis flower; edibles were second most common.
• Users reported improvements not only in pain but also in sleep quality, anxiety, and overall quality of life.

The lead researcher, Armour, subsequently published a follow-up qualitative study in Journal of Clinical Medicine (2020) exploring patient perspectives in depth, confirming cannabis as one of the most valued self-management strategies in the endometriosis community.

"Women with endometriosis are significantly more likely to use cannabis than the general population, and the vast majority of those who do report it to be effective — particularly for the pelvic pain and dysmenorrhoea that conventional medicine so often fails to adequately address." — Armour et al., 2019

CBD Topicals for Endometriosis

An emerging delivery modality specific to endometriosis is local pelvic application of CBD — via vaginal suppositories, CBD-infused tampons, or topical balms applied to the lower abdomen and pelvic region. The rationale is direct delivery of CBD to pelvic tissue, achieving higher local tissue concentrations than systemic oral or sublingual administration while minimising systemic psychoactivity.

Preclinical data supports the concept: CB2 receptor activation in pelvic peritoneal tissue reduces inflammatory cytokine release. Vaginal epithelial tissue has been shown in pharmacokinetic studies to absorb CBD into the pelvic venous plexus at meaningful concentrations following suppository administration. Several commercial products target this specific mechanism (though most are not FDA-regulated and lack standardised dosing).

For patients who prefer non-systemic options, or who need adjunct local relief during severe menstrual flares alongside systemic tinctures or capsules, CBD topicals applied to the lower abdomen (with a warm compress to enhance absorption) represent a rational complementary approach.

Hormonal Interaction Considerations

Endometriosis is an oestrogen-dependent condition — lesions depend on oestrogen for growth and survival. Cannabis’s potential hormonal interactions are therefore clinically relevant:

• CBD and aromatase (CYP19A1): In vitro data suggests CBD inhibits aromatase, the enzyme that converts androgens to oestrogens. If this translates to clinical oestrogen reduction, it could theoretically reduce endo lesion stimulation. However, clinical significance at therapeutic CBD doses has not been demonstrated in human studies.
• THC and LH/FSH: High-dose THC has been associated with alterations in luteinising hormone (LH) and follicle-stimulating hormone (FSH) pulsatility in some studies — potentially affecting ovulation. This may be relevant for patients trying to conceive.
• Interaction with hormonal therapies: Combined oral contraceptives and GnRH agonists are metabolised by CYP3A4 and CYP2C9. CBD inhibits both enzymes, potentially altering drug levels. If on hormonal therapy, inform your gynaecologist about cannabis use.
• Fertility: High-frequency THC use has been associated with reduced fertility in some observational data. For endometriosis patients actively trying to conceive, minimise THC and prefer CBD-dominant products. Discuss with a reproductive endocrinologist.

Best Strains for Endometriosis

Delivery Methods and Protocols

Menstrual Pain Protocol

1. Day before expected menstruation: Start sublingual CBD 10–20 mg twice daily as pre-emptive anti-inflammatory.
2. Day 1–2 (heaviest flow/worst pain): Add THC 5–10 mg at night (capsule or tincture). For breakthrough acute cramping: vaporise 1–2 puffs of ACDC or Harlequin.
3. Apply topical: CBD pelvic balm or warm compress with CBD oil on the lower abdomen during peak pain hours.
4. Titrate as needed: Increase THC by 2.5 mg per cycle if inadequate relief. Keep a pain diary tracking NRS pain score, cannabis dose, and menstrual characteristics.
5. Post-menstrual maintenance: Continue CBD 5–10 mg daily between cycles for sustained anti-inflammatory effect.

Psychological Burden and Cannabis as a Dual-Action Tool

The psychological toll of endometriosis is profound and frequently under-addressed in clinical care. Studies consistently show that endometriosis patients have significantly elevated rates of anxiety (up to 86% in some samples), depression (47–86%), and PTSD-like trauma responses arising from years of invalidated pain, repeated surgical interventions, and reproductive uncertainty. Catastrophising — a cognitive pattern of amplifying and dwelling on pain — is common and directly worsens pain perception through descending pain modulation pathways.

Cannabis offers a dual therapeutic dimension here that conventional pain management does not. CBD acts as a potent anxiolytic at the 5-HT1A serotonin receptor, reducing anticipatory anxiety around menstrual cycles, dyspareunia fear, and the hypervigilance that characterises chronic pain states. In one 2011 Neuropsychopharmacology study, Bergamaschi et al. demonstrated that CBD 600 mg significantly reduced anxiety in a simulated public speaking paradigm — a robust anxiogenic model. While endo-specific CBD anxiety trials are lacking, the pharmacological mechanism is well-established.

THC’s euphoric and mood-elevating properties, when used at low-to-moderate doses, can interrupt the negative affect cycle that often accompanies endo pain flares — the demoralising experience of severe pain on top of pre-existing depression. Several patients in the Armour 2020 qualitative follow-up specifically noted that cannabis’s effect on their emotional state and capacity to cope with pain was as valuable as the direct analgesic effect.

Critically, this dual action — somatic pain relief and psychological regulation — is achieved with a single agent, compared to the polypharmacy burden that many endo patients carry (NSAIDs + antidepressants + anxiolytics + hormonal therapy + sleep aids).

Qualifying Conditions and Medical Cannabis Access

Endometriosis is explicitly listed as a qualifying condition for medical cannabis in several US states including: New York, Illinois, Connecticut, Minnesota, Missouri, and New Hampshire. In additional states (California, Colorado, Massachusetts, Oregon, Washington, and others), physicians can certify any chronic debilitating condition — meaning endometriosis patients can typically access the medical programme with a sympathetic certifying physician even where it is not listed explicitly.

In Australia, endometriosis patients have accessed medical cannabis via the Therapeutic Goods Administration (TGA) Special Access Scheme-B, which allows unapproved therapeutic goods for serious conditions. Canadian patients with endometriosis can access cannabis under the medical cannabis framework via a healthcare practitioner authorisation. In the UK, cannabis-based medicinal products (CBMPs) remain restricted to specialist prescription but gynaecological chronic pain patients have obtained prescriptions via the private clinic route.

Frequently Asked Questions

Can cannabis reduce or shrink endometriotic lesions?

This is the most promising and most preliminary question in endo cannabis research. The Bouchard 2010 study showed that CB1 activation reduced the survival and invasiveness of endometriotic cells in vitro — a cell-culture finding that cannot be extrapolated directly to clinical lesion reduction. No human clinical trial has evaluated whether cannabis use is associated with slower lesion progression or reduced lesion volume on imaging. Animal model data (using rats with surgically induced endometriosis-like lesions) has shown cannabinoid treatment reduces lesion size in some models — but animal-to-human translation in endo research has historically been poor. Until clinical trials are conducted, the evidence for lesion modification remains preclinical only.

Is it safe to use CBD during the IVF two-week wait or while trying to conceive?

This is a critical question for endometriosis patients, among whom infertility affects 30–50%. The safest evidence-based recommendation is to pause all cannabis — including CBD — when actively attempting conception and during the two-week wait. Reasons: THC has documented effects on embryo implantation in animal models via CB1 signalling in the endometrium; CBD’s hormonal interactions (aromatase, LH, FSH pulsatility) are incompletely characterised; no safety data exists for CBD during early embryo development in humans. The benefit-risk calculation strongly favours cessation during active fertility treatment. Use cannabis during non-conception cycles and during menstrual symptom management, then discontinue during the two-week wait.

Are CBD suppositories and pelvic products actually effective?

The theoretical pharmacokinetic rationale is sound — vaginal epithelial tissue is highly vascular and CBD can reach pelvic peritoneal tissue at meaningful concentrations via the uterovaginal plexus without significant first-pass metabolism. However, no randomised controlled trial has specifically evaluated CBD suppositories for endometriosis. Several small case series and patient surveys (many conducted by the companies producing these products) report significant symptom relief, but publication bias is a concern. The available pharmacokinetic modelling and the established CB2 receptor density in pelvic tissue support the concept. For patients who have not responded adequately to systemic CBD alone, adding a pelvic CBD suppository during menstrual days 1–2 is a rational adjunct — but expectations should be calibrated against the limited evidence base.

Can I combine cannabis with NSAIDs for endometriosis pain?

Yes — and combining the two is mechanistically rational. NSAIDs (ibuprofen, naproxen) and CBD both reduce PGE2 prostaglandin production, but via different pathways: NSAIDs directly inhibit COX-2 enzyme, while CBD reduces COX-2 gene expression upstream. The combined effect may be additive. Additionally, THC’s central analgesic activity (via opioid receptor modulation) and muscle-relaxant properties address dimensions of endo pain that NSAIDs cannot. One practical consideration: high-dose ibuprofen combined with CBD can theoretically increase bleeding time (both have mild anticoagulant properties). Use standard NSAID doses and avoid CBD above 200 mg/day if on regular NSAIDs.

How long before I see results for endometriosis symptoms?

For acute menstrual pain, onset depends on delivery method: vaporised cannabis acts within 2–10 minutes; sublingual tinctures within 15–45 minutes; edibles within 45–90 minutes. For the chronic inflammatory and neuropathic components of endo pain — peripheral sensitisation, central sensitisation, and NGF-driven nerve fibre hypersensitivity — regular daily CBD use for 4–8 weeks is typically required before the full anti-inflammatory and neuromodulatory effects stabilise. Most patients using cannabis for endometriosis report that it takes 2–3 menstrual cycles of consistent use to determine optimal dose and timing. Keep a symptom diary tracking pain scores (NRS 0–10), cannabis dose, time of administration, and menstrual day to establish your optimal protocol.